| 12/11/2025 | CVLM | Sarepta to swap $291.4 million 2027 convertibles for 2030 notes
|
| 8/22/2025 | CV | Market Commentary: Redwood Trust prices tap of convertible notes; TeraWulf adds; NIO jumps; Sarepta active
|
| 8/22/2025 | CV | Market Commentary: Morning Commentary: Redwood Trust prices tap of convertible notes; Sarepta trades
|
| 8/21/2025 | CV | Market Commentary: Novavax, Sarepta, RealReal issue new convertible notes in private exchange transactions
|
| 8/21/2025 | CVLM | Sarepta Therapeutics begins exchange offer for 1.25% convertibles
|
| 8/21/2025 | CV | Market Commentary: Morning Commentary: Novavax, Sarepta issue new convertible notes in private exchanges
|
| 7/30/2025 | CV | Market Commentary: Celcuity convertibles skyrocket on debut; Sarepta rebound continues; Hims & Hers climbs
|
| 7/29/2025 | CV | Market Commentary: Celcuity convertible notes offering eyed; CenterPoint flat on debut; Sarepta surges
|
| 7/24/2025 | CV | Market Commentary: AST offers convertibles; MARA’s new convertibles swamp secondary; Sarepta slides
|
| 7/22/2025 | CV | Market Commentary: Sarepta convertibles stage small recovery after morning plunge; MakeMyTrip paper better
|
| 7/22/2025 | CV | Market Commentary: Morning Commentary: Sarepta Therapeutics convertibles slide, stock hits annual low
|
| 7/18/2025 | CV | Sarepta Therapeutics issues statement on gene therapy drug Elevidys
|
| 7/18/2025 | CV | Market Commentary: BlackSky convertible notes shoot to the moon; Sarepta does about face, collapses
|
| 7/17/2025 | CV | Market Commentary: BlackSky to price overnight; Lucid surges on robo-taxi partnership; Sarepta rebounds
|
| 7/17/2025 | CV | Market Commentary: Morning Commentary: Lucid convertibles surge on robo-taxi partnership; Sarepta rebounds
|
| 7/16/2025 | BKCV | Sarepta plans strategic restructuring to keep revolver access, allow convertibles’ repayment
|
| 6/16/2025 | CV | Market Commentary: MakeMyTrip convertibles on deck; Sarepta tanks in heavy volume; EchoStar shoots higher
|
| 6/16/2025 | CV | Market Commentary: Morning Commentary: Sarepta, EchoStar convertible notes in focus early
|
| 5/7/2025 | CV | Market Commentary: Sarepta convertible notes in focus; Halozyme gains; Lantheus plunges
|
| 5/7/2025 | CV | Market Commentary: Morning Commentary: Sarepta convertible notes in focus with biotechs under pressure
|
| 3/18/2025 | CV | Market Commentary: Sarepta convertible notes in focus, gain on hedge as stock drops; Lucid improves
|
| 3/18/2025 | CV | Market Commentary: Morning Commentary: Sarepta convertible notes in focus, improve on hedge as stock drops
|
| 6/21/2024 | CV | Market Commentary: Hertz clears the convertible primary market with first PIK note in decades; Sarepta jumps
|
| 6/21/2024 | CV | Market Commentary: Morning Commentary: Hertz clears the convertible primary market with first PIK note in decades
|
| 10/31/2023 | CV | Market Commentary: Western Digital spinoff complicates convertibles offering; Sarepta, Spirit, JetBlue drop
|
| 10/31/2023 | CV | Market Commentary: Morning Commentary: Western Digital spinoff complicates convertible notes offering
|
| 6/29/2023 | CV | Market Commentary: American Water exchangeables lower on bond move; Sarepta gains; Greenbriar outperforms
|
| 6/29/2023 | CV | Market Commentary: Morning Commentary: Sarepta convertible notes active amid recent stock volatility
|
| 5/24/2023 | CV | Market Commentary: Duke, CMS, Welltower hit new lows; Sarepta, PTC Therapeutics down outright, up on swap
|
| 5/15/2023 | CV | Market Commentary: Sarepta convertibles soar on FDA fast-track status for drug; Bloom Energy regains par
|
| 5/15/2023 | CV | Market Commentary: Morning Commentary: Sarepta convertibles soar on FDA fast-track status for drug
|
| 3/17/2023 | CV | Market Commentary: Convertibles quiet amid volatility; Alliant, Southern Co. active; Sarepta up on swap
|
| 3/17/2023 | CV | Market Commentary: Morning Commentary: Sarepta convertible notes in focus as stock plunges in early trading
|
| 12/21/2022 | CV | Market Commentary: Pebblebrook Hotel Trust convertibles fall on slashed guidance; Sarepta hits new heights
|
| 12/21/2022 | CV | Market Commentary: Morning Commentary: Sarepta convertibles show early gains on strong day for equities
|
| 11/28/2022 | CV | Market Commentary: MicroStrategy convertible notes for sale; Sarepta gains; Southwest Airlines active
|
| 10/18/2022 | CV | Market Commentary: Convertibles secondary firms; Sarepta hits new high, expands dollar-neutral; MongoDB up
|
| 10/18/2022 | CV | Market Commentary: Morning Commentary: Sarepta convertible notes hit new outright high; MongoDB gains
|
| 9/27/2022 | CV | Market Commentary: Convertibles secondary quiet amid volatility; high-grade notes active; Sarepta weakens
|
| 9/27/2022 | CV | Market Commentary: Morning Commentary: Sarepta convertible notes active early, weaken dollar-neutral
|
| 9/21/2022 | CV | Market Commentary: Convertibles secondary prepositions for Fed; Zendesk buyout trades continue; DISH up
|
| 9/21/2022 | CV | Market Commentary: Morning Commentary: Sarepta convertible notes active ahead of Fed decision on rates
|
| 9/19/2022 | CV | Sarepta greenshoe lifts 1.25% five-year convertibles to $1.15 billion
|
| 9/19/2022 | CV | Market Commentary: Royal Caribbean convertible notes hit new high; DISH weaker; Sarepta notes contract
|
| 9/19/2022 | CV | Market Commentary: Morning Commentary: Sarepta convertible notes continue to gain on quiet morning
|
| 9/15/2022 | CV | Market Commentary: NextEra equity units contract on debut; Sarepta convertibles add outright; Alnylam gains
|
| 9/14/2022 | CV | Market Commentary: NextEra on tap; Sarepta convertibles in focus, expand on debut; Alnylam, iQIYI active
|
| 9/14/2022 | CV | Market Commentary: Morning Commentary: Sarepta convertible notes in focus early, expand on trading debut
|
| 9/14/2022 | CV | New Issue: Sarepta prices $1 billion five-year convertible notes to yield 1.25%, up 35%
|
| 9/13/2022 | CV | Market Commentary: Sarepta convertibles eyed; Alnylam flat outright, expands on swap; Wayfair falls
|
| 9/13/2022 | CV | Market Commentary: Morning Commentary: Alnylam convertibles flat outright, expand on swap; Sarepta eyed
|
| 9/12/2022 | CV | Market Commentary: Sarepta on tap; Alnylam offering oversubscribed; Wayfair gains continue; Nio, Li Auto up
|
| 9/12/2022 | CV | Sarepta talks $1 billion five-year convertible notes to yield 1.25%-1.75%, up 32.5%-37.5%
|
| 1/8/2021 | CV | Market Commentary: Summit Hotel convertibles soar on debut; Sarepta tanks outright, jumps dollar-neutral
|
| 1/8/2021 | CV | Market Commentary: Morning Commentary: Summit Hotel convertibles upsized, trade up on debut; Sarepta eyed
|
| 12/13/2019 | CV | Market Commentary: Biotech space firm; Sarepta convertible skyrockets; Ionis notes gain; Lumentum up again
|
| 12/13/2019 | CV | Market Commentary: Morning Commentary: Sarepta convertible notes break double par; biotech space firm
|
| 11/14/2018 | CV | Market Commentary: Great Ajax on tap; Wayfair eyed, old convertibles contract; HC2 prices; Sarepta active
|
| 6/19/2018 | CV | Market Commentary: Sarepta convertibles skyrocket; PTC Therapeutics drops; Canopy gains; Sea, Twitter active
|
| 11/13/2017 | CV | Market Commentary: Rambus, Quotient announce new deals, Square Inc. jumps, recent issues in demand
|
| 11/10/2017 | CV | Market Commentary: Convertibles secondary market stable despite new issues, increased credit spreads
|
| 11/10/2017 | CV | Market Commentary: Morning Commentary: Sarepta trades actively again with convertibles, shares higher; chip names eyed
|
| 11/10/2017 | CV | Sarepta greenshoe lifts 1.5% seven-year convertibles to $570 million
|
| 11/9/2017 | CV | Market Commentary: New deals from Sarepta, Insulet trade high on reputation, new issuance drought
|
| 11/9/2017 | CV | Market Commentary: Morning Commentary: Sarepta’s upsized 1.5% notes ‘well received’ in market debut
|
| 11/8/2017 | CV | Market Commentary: Insulet, Arbor Realty deals hit market; Sarepta upsizes deal; GNC and Aegean Marine plummet
|
| 11/8/2017 | CV | New Issue: Sarepta Therapeutics sells upsized $475 million seven-year convertibles at 1.5%, up 40%
|
| 11/8/2017 | CV | Market Commentary: Morning Commentary: New Insulet 1.375% convertibles trade above par, high demand
|
| 11/7/2017 | CV | Market Commentary: Apollo add-on active in trading, Insulet deal upsized, Sarepta Therapeutics plans new deal
|
| 11/7/2017 | CV | Sarepta Therapeutics talks $375 million seven-year convertible notes to yield 1.5%-2%, up 35%-40%
|
| 11/7/2012 | CVHYPF | Sarepta Therapeutics files automatic shelf for stock, preferreds, debt
|
